People · Operator
Named in public records as an officer, director or promoter · active 2015–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. | — | Biotechnology | Series C | $70.0M | $2.9B | 2015 |
| IFM Cinque, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2019 |
| IFM Quattro, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2019 |
| IFM Continua, Inc. | — | Biotechnology | Pre-Seed | $350K | $19.3M | 2019 |
John Leonard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Leonard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 4 | 17 |
| Shelley Chu | 3 | 10 |
| Gary Glick | 3 | 7 |
| Carl Gordon | 1 | 24 |
| Nessan Bermingham | 1 | 3 |
| Rachel Haurwitz | 1 | 2 |
| Jose Rivera | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.